Also, in breast cancer, IGFBP‐2 exerts malignant potential, and again, this depends on the RGD‐motif but involves regulation of estrogen receptors as demonstrated by the Perks laboratory (Foulstone et al., 2013). This evidence concerns the gene ESR1 and breast carcinoma.